Fusion Antibodies PLC Director dealing (0041C)

TIDMFAB

RNS Number : 0041C

Fusion Antibodies PLC

16 January 2018

16 January 2018

Fusion Antibodies plc

("Fusion" or the "Company")

Director+ dealing

Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  -------------------------------------------------------------- 
 a)   Name                       Sonya Ferguson 
---  -------------------------  ----------------------------------- 
 2    Reason for the notification 
---  -------------------------------------------------------------- 
 a)   Position/status            Senior Independent Director 
---  -------------------------  ----------------------------------- 
 b)   Initial notification       Initial notification 
       /Amendment 
---  -------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  -------------------------------------------------------------- 
 a)   Name                       Fusion Antibodies plc 
---  -------------------------  ----------------------------------- 
 b)   LEI                        213800KBAYRC9VOQ9V39 
---  -------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  -------------------------------------------------------------- 
 a)   Description of             Ordinary shares of GBP0.04 
       the financial              each in Fusion Antibodies 
       instrument, type           plc 
       of instrument              Identification code (ISIN) 
       Identification             for Fusion Antibodies 
       code                       plc ordinary shares: GB00BDQZGK16 
---  -------------------------  ----------------------------------- 
 b)   Nature of the              Purchase of shares 
       transaction 
---  -------------------------  ----------------------------------- 
 c)   Price(s) and volume(s)       Price(s)   Volume(s) 
                                   ---------  ---------- 
                                    160p       15,593 
                                   ---------  ---------- 
---  -------------------------  ----------------------------------- 
 d)   Aggregated information     N/A 
       - Aggregated volume 
       - Price 
---  -------------------------  ----------------------------------- 
 e)   Date of the transaction    15 January 2018 
---  -------------------------  ----------------------------------- 
 f)   Place of the transaction   London Stock Exchange, 
                                  AIM (XLON) 
---  -------------------------  ----------------------------------- 
 

The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

Enquiries:

 
 Fusion Antibodies plc                www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive                 Via Walbrook PR 
  Officer 
 James Fair, Chief Financial 
  Officer 
 
 Allenby Capital Limited                   Tel: [phone] 
                                                          5656 
 Virginia Bull / James Reeve 
  / Asha Chotai 
 
 Walbrook PR                       Tel: [phone] or 
                                         [e-mail] 
 Paul McManus                         Mob: [phone] 
 Anna Dunphy                          Mob: [phone] 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHSFFFSMFASESF

(END) Dow Jones Newswires

January 16, 2018 05:06 ET (10:06 GMT)